DUBLIN--(BUSINESS WIRE)--The "Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
The report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Familial Chylomicronemia (Type I Hyperlipoproteinemia) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
The report assesses the active Familial Chylomicronemia (Type I Hyperlipoproteinemia) pipeline products by developmental stage, product type, molecule type, and administration route.
Scope of the report
- The report provides a snapshot of the pipeline development for the Familial Chylomicronemia (Type I Hyperlipoproteinemia)
- The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Familial Chylomicronemia (Type I Hyperlipoproteinemia)
- The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Familial Chylomicronemia (Type I Hyperlipoproteinemia)
-
The report also covers the dormant and discontinued pipeline projects
related to the Familial Chylomicronemia (Type I Hyperlipoproteinemia)
Key Topics Covered:
1. Report Introduction
2. Familial Chylomicronemia (Type I Hyperlipoproteinemia) Overview
3. Pipeline Therapeutics
- An Overview of Pipeline Products for Familial Chylomicronemia (Type I Hyperlipoproteinemia)
4. Comparative Analysis
5. Products in Clinical Stage
- Product Description
- Research and Development
- Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
- Product Description
- Research and Development
- Product Development Activities
7. Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
8. Inactive Products
- Product Description
- Research and Development
-
Product Development Activities
Companies Mentioned
- Aegerion Pharmaceuticals Inc.
- Catabasis Pharmaceuticals Inc.
- CymaBay Therapeutics Inc.
- Kadmon Corporation LLC
- Novartis AG
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/10vaal